



























Resveratrol (3,5,4’-trihydroxystilbene) was first isolated 
from the roots of white hellebore (Veratum 
grandiflorum O. Loes) in 1940 [1], and later, in 1963 
from the roots of Polygonum Cupsidatum, a plant used 
in traditional Chinese and Japanese medicine [2]. 
However, the first real interest in this compound came 
when in 1992 resveratrol was postulated to explain 
some of the cardio-protective effects of red wine [3] and 
was suggested to be an important factor in the French 
Paradox, a term coined to describe the observation that 
the French population has a very low incidence of 
cardiovascular disease, despite a diet high in saturated 
fat [4]. Five years later, in 1997, Jang and colleagues 
reported resveratrol to work as a chemo-preventive 
agent, by the ability to inhibit carcinogenesis at multiple 
stages [5]. Meanwhile, also anti-inflammatory and anti-
oxidant properties were identified for resveratrol (see 
reference [6, 7] for review). Interest in resveratrol 
peaked after 2003, when Howitz and colleagues [8] 
identified resveratrol as a potent SIRT1 activator 
capable of mimicking the effects of calorie restriction 
[9, 10] and regulating longevity in lower organisms, by 
extending lifespan in yeast [8], worms [11], flies 
(although some controversy remains for this organism 
[12, 13]) and in short-lived fish [14]. Although there are  
 
 



























a considerable amount of data supporting the role for 
resveratrol in SIRT1-mediated lifespan extension, 
recent data by Burnett et al. [15], however, suggest that 
SIRT1 may not increase longevity in Caenorhabditis 
elegans and Drosophila melanogaster. Currently  the 
exact role of resveratrol and SIRT1 in longevity is still 
under debate. What however remains uncontested is that 
resveratrol does appear to delay or attenuate many age-
related chronic diseases in animal models [16]. Given 
these beneficial effects in animal models, the eventual 
therapeutic effects of resveratrol merit to be 
investigated in humans. The first reports of such studies 
are demonstrating that also in human metabolic 
diseases, resveratrol may improve overall metabolic 
health status [17, 18]. 
 
Bio-availability and dosage of resveratrol 
 
Resveratrol is a small polyphenol found in various 
berries, nuts, and other plant sources [6]. A number of 
studies have demonstrated that resveratrol and other 
polyphenols have a very low bioavailability, leading to 
the concern that many of the beneficial health effects 
observed in either cells or biochemical assays, may not 
be achievable in humans due to rapid metabolism [19]. 
























age‐related  metabolic  diseases  the  beneficial  effects  of  resveratrol  on  metabolism  and  healthy  aging  in  humans  are
currently a topic of intense investigation. 
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is “what dose of resveratrol should be used?”.  
 
The bioavailability and pharmacokinetics of resveratrol 
has been extensively studied in humans as well as 
experimental animals. In humans, resveratrol is rapidly 
taken up after oral consumption of a low dose, with the 
plasma resveratrol concentration peaking about 30 
minutes after consumption [19]. Up to 70% of the 
ingested resveratrol has been found to be bioavailable in 
humans based on the levels appearing in the plasma 
[20], with similar levels being reported for rats (~50%) 
[21]. Both in rats and humans, resveratrol is suggested 
to undergo an enterohepatic cycle of metabolism. That is, 
after being taken up quickly by the enterocytes, 
resveratrol is metabolized to glucuronide and sulfate 
conjugates, which are secreted back to the intestine 
where they may be deconjugated and reabsorbed or 
excreted in the faeces [20, 21]. The enterohepatic cycle 
thus reduces the concentration of the free compound 
reaching the different target tissues in the body. In that 
respect, the low concentration of resveratrol in the 
blood is likely explained by the enterohepatic cycle, 
together with rapid metabolism in the liver. The 
glucuronide and sulfate conjugates, including disulfates 
and mixed sulfate-glucuronides, are the major 
metabolites being formed, apart from dihydroresveratrol 
[22].  
 
So, it is clear that only a small fraction of the ingested 
resveratrol reaches the body tissues as resveratrol. 
Furthermore, the amount of resveratrol ingested from 
dietary sources, such as red wine and juices (rarely 
exceeding 5 mg/l), often results in plasma levels that are 
either not detectable or several orders of magnitude 
below the micromolar concentrations that are employed 
in vitro (~32 nM – 100 μM) [23]. For example, 
administration of about 25 mg resveratrol results in 
plasma concentrations of the free form that range from 
1 to 5 ng/ml [24] and administration of higher doses (up 
to 5 g) increased the plasma resveratrol concentration to 
about 500 ng/ ml [25].  
 
The low doses of resveratrol observed in the plasma 
after ingestion are worrisome, as the concentrations 
used in vitro are not reached. However, one must bear 
in mind that resveratrol is lipophilic, meaning that it 
mixes very well with lipids including membranes and 
lipoproteins. Therefore, the tissue resveratrol levels may 
in fact be higher than what is suggested based on 
plasma levels. However, some of the biological effects 
of resveratrol are also observed at a very low 
concentration [26, 27], bringing forward the idea that 
resveratrol exerts its major effects on the intestinal 
tissue, affecting the rest of the body through secondary 
effects that are indispensible of the plasma levels 
reached by the compound [6]. 
 
In rodent models, the doses employed normally range 
from as low as 0.1 mg/kg up to 1,000 mg/kg, with even 
higher or lower doses occasionally being used [6]. 
Moreover, resveratrol has been show to exert biphasic 
effects [28]. That is, resveratrol employed at low doses 
(~ 5 mg/kg/d) has been shown to cause weight gain in 
mice on a high-fat diet [29], whereas at high doses (~ 
400/mg/kg/d), there is marked weight loss [10]. Also, 
cardioprotective effects of resveratrol that are observed 
at 2.5 or 5 mg/kg/d are reversed when the dose is 
increased to 25 or 50 mg/kg/d [30]. These results may 
suggest that resveratrol acts via multiple target 
pathways, and as such, calculating the effective in vivo 
concentration of resveratrol or designing new studies 
based on current literature is challenging. Further 
experiments are necessary to show whether resveratrol 
or its metabolites accumulate sufficiently in tissues to 
account for the widespread acclaimed role of resveratrol 
in the treatment of various diseases. But even if the 
optimal dose for rodent experiments is determined, the 
question still remains how to extrapolate to a human 
equivalent dose. Direct extrapolation by body weight is 
often used as a guideline, however, as proposed by 
others, body surface area might be a better option [31].  
 
Mechanism of action of resveratrol 
 
The exact mechanisms through which resveratrol exerts a 
wide range of beneficial effects across species and 
disease models is currently still unclear [6]. Similar to 
most other polyphenols, resveratrol is suggested to 
possess intrinsic anti-oxidant capacity, but it is also 
implicated to induce the expression of a number of anti-
oxidant enzymes, with probably both mechanisms 
contributing to an overall reduction in oxidative stress 
[32]. Resveratrol further interacts with a large number of 
receptors, kinases, and other enzymes that could plausib-
ly make a major contribution to its biological effects.  
 
In 2003 Howitz and colleagues proposed that 
resveratrol is capable of increasing the deacetylase 
activity of Sirtuin 1 (SIRT1), a genetic modulator that is 
part of the health-promoting pathway that is activated 
by calorie restriction [8]. It has already been known 
since the 1930s that a severe lowering of calorie intake 
dramatically slows the rate of ageing in mammals and 
lowers the onset of numerous age-related diseases, 
including cancer, cardiovascular disease, diabetes and 
neurodegeneration [33, 34]. 
 
Sirtuins are a conserved family of NAD
+-dependent 
deacetylases (class III histone deacetylases) that were 
   
www.impactaging.com                    147                                         AGING, March 2012, Vol.4 No.3named after the founding member, the Saccharomyces 
cerevisiae silent information regulator 2 (Sir 2) protein 
[35]. A number of subsequent studies showed that 
resveratrol induced SIRT1 activity in several species 
(for review see [36]). Furthermore, resveratrol mimics 
numerous aspects of calorie restriction in all eukaryotes 
tested to date [8-11, 14, 29, 37] and in most of them, the 
effect appears dependent on SIRT1 [8, 10, 11]. In line 
with being an activator of SIRT1, several studies [8, 9, 
11, 14], however not all [29], reported that resveratrol 
increased lifespan. Resveratrol was also shown to 
increase energy expenditure in mice [9, 10], through 
increased SIRT1 activation, and during conditions of 
high fat availability, resveratrol was capable of 
preventing diet-induced obesity and the onset of 
obesity-related metabolic diseases, so ultimately 
protecting mice against the lifespan curbing effects 
associated with high calorie intake. The molecular 
mechanism underlying these beneficial effects seem to 
depend on the resveratrol-induced increase in 
mitochondrial content, which is explained by increased 
signalling through the SIRT1/ PGC1α axis [10].  
 
More recently, some studies have questioned the direct 
activation of SIRT1 by resveratrol [38, 39]. That is, 
both reports showed that measuring SIRT1 activity by 
means of the non-physiological fluorescent “Fluor de 
Lys” substrate assay could lead to artificial results [38, 
39]. Furthermore several reports demonstrate that 
resveratrol can also activate AMPK [9, 40-42], which 
reconciles with the positive effect on the mitochondrial 
respiratory chain that has been reported [43]. Hawley et 
al. [44] reported that resveratrol-induced AMPK 
activation in isogenic cell lines, stably expressing 
AMPK complexes containing AMP- insensitive γ2 
subunit variants (R531G), derives from an AMP/ATP 
imbalance as a consequence of interference with 
mitochondrial respiration. Although the idea was put 
forward that the resveratrol-induced AMPK activation 
was dependent on SIRT1 [45], the use of mouse 
embryonic fibroblast cells from SIRT1 knock-out mice 
unequivocally demonstrated that SIRT1 is dispensable 
for resveratrol-induced AMPK activation [40, 46]. On 
the contrary, resveratrol cannot activate SIRT1 in the 
absence of functional AMPK [46, 47]. So, the current 
working mechanism of resveratrol that evolved from all 
these reports is that SIRT1 functions as the downstream 
mediator of AMPK, instead of being a direct molecular 
target of resveratrol. Canto et al. [48] have shown in 
that respect that the AMPK induced increase in NAD
+ 
levels, as a consequence of increased fatty acid 
oxidation, leads to SIRT1 activation.  
 
Currently, activation of AMPK seems to be a major 
target of resveratrol’s actions, providing a plausible 
explanation for a large part of the health benefits 
observed in reports published to date. However, fully 
defining the targets of resveratrol that are biologically 
relevant is an enormous task, made more difficult by the 
question whether effects are either direct or indirect. 
This issue is discussed further in [6, 7]. 
 
Obesity and diabetes 
 
In rodent models of diet-induced obesity, a high dose of 
resveratrol (400 mg/kg/d) improves insulin sensitivity 
and lowers body weight [10], which has increased the 
interest and the speculation about its potential use as an 
anti-diabetic agent in humans. However, applying a 
lower dose of resveratrol (~ 22.5 mg/kg/d) appeared 
insufficient to produce weight loss, although it still 
improved glucose tolerance [9]. In fact, low doses of 
resveratrol are shown to prolong survival in obese mice 
while simultaneously increasing body weight [29]. One 
observation that is made, is that animals supplemented 
with a high dose of resveratrol are capable of increasing 
their energy expenditure, based on their ability to 
increase their running distance or tolerate cold longer 
compared to their untreated controls. However, whether 
these observations underlie the reduction in body 
weight is not clear, as voluntary exercise is actually 
lower in the resveratrol-treated group and body 
temperature is not detectably changed under basal 
conditions [10]. Nevertheless, recent work has shown 
that a one-year intervention with resveratrol at a dose of 
200 mg/kg/d seems to cause an increase in basal 
metabolic rate and total daily energy expenditure in the 
non-human primate Microcebus murinus [49, 50]; 
indicating that resveratrol might have the potency to 
enhance energy expenditure thereby promoting weight 
loss. 
 
In 2007 already, a cross-sectional study found that 
supplemental resveratrol is taken by 2/3 of people who 
routinely consume multiple dietary supplements, and 
this number may be increasing as studies describing 
resveratrol’s health effects have reached the lay public 
through ample coverage in popular media. Because of 
the increasing public interest, and the favourable health 
effects in lower organisms, there is urgent need for 
studies examining the therapeutic potential of 
resveratrol in humans, especially since the prevalence of 
chronic metabolic diseases is reaching epidemic 
proportions worldwide.  
 
To date, the number of published clinical trials that have 
examined the effect of resveratrol on insulin sensitivity 
are still limited and several trials are currently still 
ongoing (see Table 1 for an overview of all published 
peer-reviewed clinical trials on resveratrol). However, 
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addressed the ability of resveratrol to serve as a weight 
loss compound. In 2009 a clinical study Elliott et al. 
[51] reported for the first time the effect of resveratrol 
on type 2 diabetes patients at doses of 2.5 and 5 g/day 
for 28 days. The levels of fasting and postprandial 
glucose and insulin serum levels were statistically 
significantly decreased at the dose of 5g/day, but few 
experimental details were provided in that work. In 
2011, Brasnyo et al. [52] found that a four-week 
intervention with resveratrol in type 2 diabetic men 
significantly improved insulin sensitivity. Thus, 
supplementing trans-resveratrol twice daily at a dose of 
5 mg decreased insulin resistance (computed by the 
homeostatic model assessment of insulin resistance 
HOMA-IR), lowered blood glucose levels and delayed 
the glucose peak following a standardized meal in type 
2 diabetic men (n=10) compared with placebo (n=9) 
[52]. The authors suggested that a decreased oxidative 
stress might underlie these effects, as significant 
reductions in 24 h urinary creatinine-normalized ortho-
tyrosine concentrations and an increased Akt 
phosphorylation in blood platelets was observed after 
































reported on the other hand that fasting glucose, insulin 
or HOMA-IR scores remained unchanged following a 
six-week supplementation of 40 mg resveratrol (in P. 
cuspidatum  extract) in healthy volunteers. In that 
respect it might be noteworthy to mention that also 
normal healthy mice on a chow-diet fail to improve 
their insulin sensitivity upon resveratrol 
supplementation [10], arguing that resveratrol might 
only be effective under metabolic stress conditions such 
as obesity or diabetes. Recently, a small pilot study was 
carried out that showed the potential of resveratrol 
treatment to improve glucose tolerance, insulin 
sensitivity and vascular function [17]. For this 
intervention the authors chose to study the effects of 
resveratrol in subjects with impaired glucose tolerance 
that have definite but not yet severe metabolic 
dysregulation, and therefore may be most amenable to 
intervention. After four weeks of resveratrol 
supplementation with a daily dose of 1, 1.5 or 2g, post 
meal plasma glucose was lowered in IGT subjects at 
doses between 1 and 2 g/day, whereas the insulin 
response remained unchanged [17]. Furthermore, a 
trend towards an improved post meal endothelial 


































Authors  Participants (n)  Objective  Form and 
dose of 
resveratrol 
Duration  Outcome 
Bioavailability from resveratrol supplement (as capsules or in another matrix) 
Almeida et 
al. 2009 [24] 
Healthy men (20) 









6x/day at 4h 
intervals for 13 
doses 
Peak plasma concentrations of 
trans-resveratrol were reached 
at 0.8-1.5 h post dose. 
Following the 13th dose of 
trans-resveratrol 25, 50, 100 
and 150 mg, mean peak 
plasma concentration 
(C(max)) was 3.89, 7.39, 23.1 
and 63.8 ng/mL. Inter-
individual variability was 
high. Bioavailability was 
higher after morning 
administration. Resveratrol 
was well-tolerated, but with 
some mild adverse events 
reported. 
Boocock et 
al. 2007 [25] 
Healthy men (18) 




0.5, 1, 2.5, or 5 
g capsules 
 
Single dose   Consumption  of  resveratrol 
did not cause serious adverse 
events. Resveratrol and six 
metabolites were recovered 
from plasma and urine. Peak 
plasma levels of resveratrol at  
   














































































































          the highest dose were 539 ng/mL, 
which occurred 1.5 h post-dose. 
Peak levels of two monoglucuro-
nides and resveratrol-3-sulfate were 
3- to 8-fold higher. The AUC 
values for resveratrol-3-sulfate and 
resveratrol monoglucuronides were 
up to 23 times greater than those of 
resveratrol. Urinary excretion of 
resveratrol and its metabolites was 
rapid, with 77% of all urinary 
agent-derived species excreted 
within 4 h after the lowest dose. 
Brown et al. 
2010 [56] 
Healthy men (22) 





0.5, 1, 2.5, or 
5 g caplets 
Multiple, once 
daily for 29 
days 
Plasma Cmax was 958.6 μg/L 
following 29 days of 5 g. Cmax 
and total AUC for the metabolites 
dramatically exceeded those for 
resveratrol. 




al. 2008 [57] 




85.5 mg of 
peceid per 70 




100 mL of 
15% ethanol 
and made up 
with a low-fat 
milk (1.5%) to 
a total volume 
of 500 ml 
Trans-resveratrol metabolites 
formed in the plasma and urine 










bound to proteins. 
La Porte et 
al. 2010 [58] 
Healthy men (3) 












(500 mg) or 




Resveratrol in combination with a 
high-fat breakfast reduced the area 
under the plasma concentration-
time curve and the Cmax compared 
to a standard breakfast. Quercetin, 
or 5% alcohol (100 mL) did not 
influence trans-resveratrol pharma-
cokinetics. Resveratrol was well 
tolerated, although diarrhea was 
frequently observed. 
Meng et al. 
2004 [59] 
Healthy men (3)  Bioavailability 
of resveratrol 
supplement 
0.03, 0.5, or 1 
mg/kg 
dissolved in 5 
mL whisky 
mixed with 50 
mL water 
Single  Resveratrol levels were readily 
detected in the plasma and the 
urine. The recovery of resveratrol 
in the plasma suggested a rapid 
absorption of resveratrol in the 
gastrointestinal tract. 
   





















































































































0.32, 0.64, 0.96, 
or 1.92 mg 
delivered in 
grape juice 
(200, 400, 600, 
or 1200 mL) 
Single  Resveratrol was only detected 
in the urine at when 600 and 
1200 mL of grape juice were 
given. In grape juice, the level 
of free resveratrol is rather low. 
Cis- and trans-Piceid are the 
major resveratrol derivatives in 
grape juice. 
Nunes et al. 
2009 [60] 
Healthy young 
















intervals for 3 
days followed 
by a last 
single dose at 
day 4 (total of 
eight doses of 
200 mg) 
Pharmacokinetic and metabo-
lite profile. Resveratrol was 
well tolerated by young and 
elderly subjects and the kinetic 
profile was independent of age 
and gender. 







0.5, or 1 g/ day  Single dose 
for 8 days 
Trans-resveratrol (674 nmol/g) 
and resveratrol-3-O-glucuro-
nide (86 nmol/g) were 
recovered from colonic tissue. 













mL red wine, 1 
L grape juice, or 





Single Plasma  trans-resveratrol 
increased as a response to all 
grape products and that of cis-
resveratrol after wine and 
grape juice. Despite similar 
doses of trans-resveratrol being 
administered, the bioavailabili-
ty of resveratrol from wine and 
grape juice is six fold higher 
than that from tablets. 










25 mg taken 
orally and 
intravenously 
Single  Absorption is at least 70% with 
peak plasma levels of 
resveratrol and metabolites of 
around 491 ng/ml and a plasma 
half-life of 9.2 h. Most of the 
oral dose was recovered in the 
urine. Three main metabolic 
pathways were identified: 
sulfate and glucuronic acid 
conjugation of the phenolic 
goups, and hydrogenation of 
the aliphatic double bond. 
 
   





















































































































25 mg/ 70 kg 
body weight 
dissolved in 100 
mL of white 
wine (11.5% 
ethanol), white 




Single Efficient  absorption  of 
resveratrol but significant 
differences in bioavailability 
pattern between matrices, with 
plasma resveratrol concentra-
tion decreasing most rapidly 
with V8 and least rapidly 
using grape juice. 









300 mL/d intake 





Red wine 1.8 
g/L; white wine 
0.25 g/L 
15  days    Plasma resveratrol concentra-
tions increased form 0.72 to 
1.33  μmol/L for white wine 
and from 0.71 to 1.72 μmol/L 
for red wine. 
Urpi-Sarda et 






5.38 mg from 
250 mL red 
wine 
Single  Resveratrol metabolites were 
incorporated into low-density 
lipoproteins after a moderate 
intake of red wine. The 
metabolites identified in low-




O-glucoside, and free trans-
resveratrol. 
Vitaglione et 








3.4, 7.5, or 33 
μg/ kg from 300 
or 600 mL red 




standard meal, a 




Single  Free trans-resveratrol was 
found in trace amounts, only 
in some serum samples 
collected 30 minutes after red 
wine ingestion while after 
longer times resveratrol 
glucuronides predominated. 
Trans-resveratrol bioavailabi-
lity was shown to be 
independent from the meal or 
its lipid content. However, 
Wide the wide variation in 
subject responses combined 
with low bioavailability 
suggests that the combination 
of polyphenols may account 
for the French paradox. 
 
   























































































































0.357, 0.398, or 
2.56 mg/day 
from 300 mL 
sparkling wine 
or 200 mL 
either white 




for 28 days 
Significant increases in total 
resveratrol metabolites were 
observed in the urine after 
consumption of sparkling, 
white or red wine. 
Resveratrol metabolites in 
urine may be useful 
biomarkers of wine intake in 
epidemiological and 
intervention studies. 
Oxidative stress and inflammation 
Ghanim et 
al. 2010 [53] 
Healthy adults 
(20) 










Daily for 6 
weeks 
The extract induced a 
significant reduction in 
reactive oxygen species 
generation as shown by a 
decrease in the expression of 
P47 (phox), NFκB, JNK-1, 
PTP-1B, SOCS-3 in 
mononuclear cells, when 
compared to placebo and 
baseline. The extract also 
suppressed plasma 
concentrations of TNF-α, IL-6 
and CRP. 
Ghanim et 























meal with 100 
mg resveratrol 
and 75 mg 
grapeskin 
polyphenols 
2 visits, 1 
week apart 
The supplement containing 
resveratrol and muscadine 
polyphenols suppresses the 
increase in oxidative stress, 
lipopolysaccharide and 
lipoprotein binding protein 
concentrations, and expression 
of TLR-4, CD14, IL-1β and 
SOCS-3 in mononuclear cells 
after a high-fat high-
carbohydrate meal. It also 
stimulates specific Nrf-2 
activity and induces the 
expression of the related 




al. 2010 [68] 
Young healthy 










250 or 500 mg 
capsules 
Single; once 
daily on 3 
separate days 
Resveratrol dose-dependently inc
flow during task performance, 
concentrations of haemoglobin. 
enhance cognitive function.  
 
   














































































































Wong et al. 
2010 [69] 
Overweight/ 
obese men (14) 
and post-
menopausal 







30, 90, or 270 





Each dose for 
6 days 
Flow-mediated dilation of the 
brachial artery increased 45 
min following 30, 90, and 270 
mg doses of resveratrol. 
Cancer 




A phase-I pilot 
study in which the 
effects of 
resveratrol are 
examined on Wnt 
signalling in the 
normal colonic 
mucosa and colon 
cancer tissue 
4 groups: 


















Daily for two 
weeks 
Grape powder (80 g), which 
contains low doses of 
resveratrol in combination 
with other bioactive 
components, can inhibit the 
Wnt pathway in colonic 
cancer patients but this effect 
is confined to the normal 
colonic mucosa. 




 Chemo preventive 
activity 
0.5, or 1 g/ day  Single dose 
for 8 days 
Resveratrol reduced tumour 
cell proliferation by 5%. 
Chow et al. 
2010 [71] 
Healthy men (11) 
and women (31) 




1 g caplets  Once daily for 
28 days 
Resveratrol intervention 
inhibited the phenotypic 
indices of CYP3A4, 
CYP2D6, and CYP2C9 and 
induced the phenotypic index 
of 1A2. Overall, GST and 
UGT1A1 activities were 
minimally affected by the 
intervention, although an 
induction of GST-π level and 
UGT1A1 activity was 
observed in individuals with 
low baseline enzyme 
level/activity.  
Brown et al. 
2010 [56] 
Healthy men (22) 
and women (18) 
Chemo preventive 
properties 
0.5, 1, 2.5, or 5 
g caplets 
Multiple, once 
daily for 29 
days 
Resveratrol decreased 
circulating IGF-1 and IGFBP-
3 in circulating plasma. The 
decrease was most marked at 
2.5 g. The observed decrease 
might contribute to cancer 
chemo preventive activity. 
   











































We also investigated the metabolic effects of resveratrol 
in obese men [54] and were able to support the notion 
that resveratrol might have a similar mechanism of 
action in obese humans as in high-fat fed animals. 
Supplementation with resveratrol for 30 days induced 
health effects that were comparable to the effects of 
calorie restriction. Resveratrol reduced sleeping and 
resting metabolic rate in the absence of body weight 
changes. Furthermore, skeletal muscle mitochondrial 
function and fat oxidative capacity improved and 













































ed by resveratrol. Gene set enrichment analysis revealed 
that resveratrol activated similar pathways in humans 
compared to mice, as mitochondrial pathways related to 
ATP production and oxidative phosphorylation were 
upregulated and inflammatory pathways were 
downregulated. In accordance to the rodent data, we 
confirmed that resveratrol supplementation induced an 
increase in skeletal muscle SIRT1 protein levels. These 
results are especially encouraging since Rutanen et al. 
showed that low SIRT1 expression could contribute to 
the disturbance in energy balance, that is already present 
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Diabetes, obesity, and metabolism 
Elliot et al. 
2009 [51] 
Type 2 diabetics  Insulin sensitivity  2.5, or 5 g  Daily for 28 
days 
Decreased fasting and 
postprandial glucose and 
insulin at 5 g. 




Insulin sensitivity  5 mg capsules  Twice daily 
for 4 weeks 
Resveratrol significantly 
decreased insulin resistance (as 
measured by HOMA index), 
while it increased the pAkt:Akt 
ratio in platelets. 
Urinary ortho-tyrosine 
excretion (a measure of 
oxidative stress) decreased by 
resveratrol. 
Timmers et 
al. 2011 [18] 
Healthy obese 
men (11) 
Metabolic effects  75 mg of 








for 30 days 
Resveratrol improved the 
metabolic profile: resveratrol 
reduced sleeping and resting 
metabolic rate. In muscle, 
resveratrol activated the 
AMPK-SIRT1-PGC1α axis. 
Resveratrol reduced blood 
glucose and insulin levels, 
reduced liver fat storage, 
improved muscle mitochon-
drial function and reduced 
inflammation markers in the 
blood. 
Crandall et 
al. 2012 [17] 
Older men (3) 







1, 1.5, or 2 g  Daily for 4 
weeks 
Decreased peak glucose and 3-
h glucose AUC following a 
meal at 1.5 and 2 g. Matsuda 
index for insulin sensitivity 
improved at 1.5 and 2 g. Trend 
towards improved hyperemia 
index. 
 
*This table was partly based on [72, 73]. in offspring of type 2 diabetes, by reducing mitochondrial 
function [55].  
 
Though limited data is available on resveratrol’s 
efficacy in chronic metabolic diseases in humans, the 
clinical trials that are available show much promise that 
resveratrol might be applied to improve general health 
status and prevent chronic disease in humans. However, 
further research is warranted to increase our 
understanding of the physiological responses of 
resveratrol before widespread use in humans can be 
promoted. Future research should aim to explore the 
relationship between dose – bioavailability- and 
efficacy and further define the pleiotrophic mechanisms 
of actions in humans. Furthermore, chronic studies are 
an absolute must, as it is still unclear if resveratrol 
supplementation on the longer term is beneficial for 
overall health status. 
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